• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how the EMERALD trial demonstrated elacestrant’s efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific...

Managing Elacestrant Treatment: From Patient Selection to Supportive Care

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting. Read...

Honoring a Healer: Personal Care With National Impact

by MM360 Staff | May 7, 2025 | Uncategorized

Source: CureToday articles This is a joint nomination by Camille Moses and Dr. Estelamari Rodriguez. Read More

Breaking Barriers: Why Increasing Lung Screening is Critical

by MM360 Staff | May 7, 2025 | Uncategorized

Source: CureToday articles Lung cancer remains the leading cause of cancer-related deaths in the U.S. Read More

LCI Shows Support for Lung Cancer Research Funding at GO2 Voices Summit

by MM360 Staff | May 7, 2025 | Uncategorized

Source: CureToday articles Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC. Read More

Managing Lung Inflammation After Chemoradiation and Tagrisso

by MM360 Staff | May 7, 2025 | Uncategorized

Source: CureToday articles Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
  • (no title)
  • Tecvayli-Darzalex Faspro combo up for approval in 2 nations for treating RRMM
  • In vivo CAR-T exhibits activity in advanced multiple myeloma
  • FDA backs faster development of new therapy for hard-to-treat AML
  • The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
  • Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
  • Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030
  • Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT